Benign prostatic hyperplasia (BPH) is a chronic proliferative disease that may be defined as prostate glandular epithelial enlargement secondary to epithelial and stromal hyperproliferation, with a predominance of stromal cells [1]. BPH is a progressive condition of aging men that McNeal characterized as a selective benign overgrowth within the transition-periurethral zone (TPZ) proximal to the verumontanum, which can clinically result in bladder outlet obstruction and various lower urinary tract symptoms (LUTS) [2,3,4,5,6]. Beginning at age 40 years, the prevalence of BPH increases with aging. Approximately fifty percent of males can exhibit BPH symptoms by 51–60 years [7]. The prevalence of BPH was seventy percent in males by 70 years, and increases to eighty percent by 85 years [8]. The occurrence and development of BPH are closely related to age.

The human prostatic gland is composed of secretory epithelium arranged in the gland within a fibromuscular stroma composed of smooth muscle. Understanding prostate development clarifies some of the hyperplastic changes observed in BPH, since this disease has been seen historically as a type of embryonic reawakening process [4,9]. Prostatic embryonic development, subsequent pubertal and adult growth, and homeostatic maintenance are strongly regulated through androgen-dependent reciprocal paracrine interactions between stromal and epithelial components (stromal-epithelial interaction) [10]. Cell proliferation is greatly increased in BPH compared to normal prostate tissue; epithelial proliferation was 9-fold higher, while stromal proliferation was 37-fold higher [11], suggesting that BPH is a disease that has stromal-dominant proliferation. Prostate epithelial proliferation results in enlargement of glandular nodules, while stromal proliferation produces a more diffuse hyperplasia with increased extracellular matrix production including collagen type I [12]. However, the specific mechanisms that promote prostatic enlargement, as well as the pathological changes leading to the BPH phenotype, have remained unclear.

Aging and androgens are necessary for the development of BPH, but the pathogenesis of BPH is still largely unresolved [13]. Although androgen levels in men generally decrease with age, there is a paradox that prostate weight increases in BPH patients [14]. On the other hand, clinical practice has proven that a 5α-reductase inhibitor (5AR-I) can effectively reduce the level of dihydrotestosterone (DHT) in prostate tissue and reduce the risk of BPH progression, but 10% of patients still have clinical progression [15,16]. This shows that androgens are not the only factors that cause BPH. Androgen-independent factors include ischemia, oxidative stress, metabolic syndrome, infection, autoimmune reactions, and inflammation (Figure 1), and these interact with each other to form more complicated pathophysiology. In particular, inflammation has received much attention, and various studies are underway. Therefore, to elucidate the pathogenesis of BPH, an approach that focuses on androgen-independent factors is required.

BPH is characterized as a chronic, progressive, but discontinuous hyperplasia of both glandular epithelial and stromal components leading to prostatic enlargement and clinical symptoms [9,17]. Franks and McNeal emphasized the idea that BPH is one of the nodular diseases, and that BPH nodules have several types including stromal, fibromuscular, muscular, fibroadenomatous, and fibromyoadenomatous [9,18]. The stromal components of BPH also contain fibroblasts, myofibroblasts, blood vessels, nerves, and inflammatory cells. Each of these epithelial and stromal components have the possibility of being involved in the development of BPH. Histological BPH can be defined as epithelial and stromal proliferation in the prostate transition zone associated with tissue remodeling, which involves epithelial tissue and fibromuscular matrix, with a certain androgen dependence [19,20,21]. Compared with normal prostatic tissue, the balance between growth and apoptosis of stromal cells in hyperplastic nodules is lost, finally leading to an increase in stromal volume.

McNeal also reported that the adult stromal nodule had re-acquired embryonic activity and was inducing the formation of a glandular duct that was invading into the nearby stromal nodule. This concept was based on the demonstration that embryonic prostatic development is induced by urogenital sinus mesenchyme (UGM), as the embryonic reawakening theory [22].

The effect of UGM on prostatic development is one of the most basic developmental mechanisms, namely the stromal-epithelial interaction. The organs of the male and female urogenital tracts develop through stromal-epithelial interactions that are in sequence regulated by steroid hormones acting through mesenchymal and epithelial steroid receptors [23]. The importance of the stromal component in prostate proliferation has been described. In classic tissue recombination experiments, androgen signaling was reported to be required in the stroma, although it is dispensable in the epithelium for the induction of prostatic tissues [24]. In addition, mosaic ablation of the transforming growth factor (TGF) β type II receptor in a subset of fibroblasts was clarified to result in epithelial neoplasia [25,26]. Moreover, overexpression of fibroblast growth factor 10 by UGM promotes the growth of cancer in adult dissociated prostate epithelial cells grafted under the kidney capsule [27]. There are the interactions between the UGM and urogenital epithelia (UGE) in proliferative process of prostate. The UGM specifies prostatic epithelial identity and induces epithelial invading and budding, and the developing prostatic epithelium likewise induces smooth muscle differentiation and developing a pattern of UGM [28,29]. In transplantation experiments in which UGM alone is transplanted under the kidney capsule of male nude mice, a small amount of smooth muscle differentiated in the grafts [29]. On the other hand, tissue recombinants, indicating a mixture of two cells to evaluate their interaction with each other, composed of UGM and UGE induces the formation of prostatic ducts with epithelial cells surrounded by smooth muscle cells [30]. Importantly, smooth muscle cells can be specified in the UGM not only by UGE, but also by epithelium from adult prostate, presenting common inductive signals across epithelial types and stages [31]. The signaling by interaction between the epithelium and the stroma is not only crucial for prostate development, but it also continues to play key roles in maintaining prostate homeostasis in the adult prostate. These results demonstrate the importance of the stroma and stromal-epithelial interaction in the BPH proliferative process.

Several studies have reported the effectiveness of treatments targeting the stromal-epithelial interaction in BPH. One current study aims to elucidate the potential roles of bone morphogenic protein (BMP) 5 and correlated signaling pathways for the epithelial-mesenchymal transition (EMT) in BPH. This study reported that BMP5 was upregulated in human and rat hyperplastic prostate tissues and localized both in the epithelial and stromal area of prostate tissues. Overexpression of BMP5 enhanced cell proliferation and the EMT process through phosphorylation of small mother against decapentaplegic (Smad) 1/5/8, while selective knockdown of BMP5 induced cell cycle arrest at the G0/G1 phase and inhibited the EMT process. Moreover, the agonist and antagonist of BMP/Smad signaling pathway inverted the effects of BMP5 silence and overexpression, describing that BMP5 regulated cell proliferation and the EMT process through the BMP/Smad signaling pathway, which might contribute to the development of BPH [32].

Hedgehog (HH) signaling is reported to be a master regulator in numerous developmental processes [33]. HH signaling regulates ductal morphogenesis through stromal-epithelial interactions during prostate development [33]. In the adult prostate, HH signaling is active in the stromal component, and HH-responding cells show properties of stromal stem cells. The roles of HH signaling in prostate development have been previously reported by the Bushman group and others [34,35,36].

4. Stromal Proliferation in Benign Prostatic Hyperplasia